Collagen-induced platelet aggregation blocker revacept - a possible role as a dialysate additive? Print
Circulation: Conclusion— This phase I study demonstrated that Revacept is a safe and well-tolerated new antiplatelet compound with a clear dose-dependent pharmacokinetic profile with specific, dose-related inhibition of platelet aggregation despite completely unaltered general hemostasis.

...